Effect of Secretin on Gastric Accommodation, Emptying and Post-nutrient Challenge Symptoms in Functional Dyspepsia and Healthy Subjects

Overview

About this study

The purpose of this study is to compare the effects of secretin vs. saline on satiation, fasting gastric volume, gastric accommodation and emptying, and symptoms in patients with functional dyspepsia with normal gastric emptying and with that of healthy volunteers.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Able to provide written informed consent prior to any study procedures and be willing and able to comply with study procedures.
  • No medical problems or chronic diseases that could significantly affect GI function, other than functional dyspepsia, for that group.
  • Body mass index of 18-40 kg/m2.
  • Female subjects must have negative urine pregnancy tests and must not be lactating prior to receiving study medication and radiation exposure. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. Female subjects unable to bear children must have this documented in the medical record [i.e., tubal ligation, hysterectomy, or post-menopausal (defined as a minimum of one year since the last menstrual period)].
  • Rapid or normal gastric emptying (GE) measured via scintigraphy in past 5 years for FD subjects.
  • Normal upper endoscopy (EGD) in past 5 years for FD subjects.

Exclusion Criteria:

  • Significant change in symptoms since previous EGD and/or GE study for FD subjects.
  • Unable or unwilling to provide informed consent or to comply with study procedures.
  • Structural or metabolic diseases that affect the GI system.
  • Unable to stop acid reducers such as proton pump inhibitors, H2 blockers 3 days prior to study days:
    • May permit antacids on as needed basis but must stop 8 hours before study days.
  • Unable to avoid the following over-the-counter medications 48 hours prior to the baseline period and throughout the study:
    • Medications that alter GI transit or motor function including laxatives, magnesium and aluminum containing antacids, prokinetics, erythromycin, buspirone, clonidine, tricyclic antidepressants, and secretin-norepinephrine reuptake inhibitors, buproprion, benzodiazepine, anticholinergics (tricyclic antidepressants, trazodone, cyclobenzaprine, antihistamines), anti-emetics (promethazine, prochloperazine, ondansetron)
    • Analgesic drugs including NSAIDs and COX-2 inhibitors.
    • NOTE:  Stable doses of thyroid replacement, estrogen replacement, low-dose aspirin for cardio protection, low stable dose antidepressants of the SSRI class, and birth control (but with adequate backup contraception, as drug interactions with birth control have not been conducted) are permissible.
  • History of recent surgery (within 60 days of screening).
  • Acute or chronic illness or history of illness which in the opinion of the investigator could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data, such as frequent angina, Class III or IV congestive heart failure, moderate impairment of renal or hepatic function, poorly controlled diabetes, etc.
  • Any clinically significant abnormalities on physical examination or laboratory abnormalities identified in the medical record, as determined by the investigator.
  • Acute GI illness within 48 hours of initiation of the baseline period.
  • Females who are pregnant or breastfeeding.
  • History of excessive alcohol use or substance abuse.
  • Participation in an investigational study within the 30 days prior to dosing in the present study.
  • Any other reason, which in the opinion of the investigator, would confound proper interpretation of the study.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Camilleri, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20432323

Mayo Clinic Footer